Making cell therapies is no easy task. Unlike small molecule pills, or even protein-based drugs, cell therapies consist of whole living cells, which are carefully modified to express specific target-seeking receptors and then multiplied many times over.
Even Novartis, which with Kymriah won the first U.S. approval of a CAR-T therapy, has repeatedly run into challenges making the treatment to its approved specifications.
